ArticleEJNMMI radiopharmacy and chemistry2018
Synthesis of an Al
Article in EJNMMI radiopharmacy and chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Optimization of a GMP-compliant automated one-pot synthesis of Al[EJNMMI radiopharmacy and chemistry · 2025Article
- Comparative Evaluation of (World journal of nuclear medicine · 2025Article
- Article
- Optimization and scale up of production of the PSMA imaging agent [EJNMMI radiopharmacy and chemistry · 2024Article
- Molecular Imaging of Monoamine Oxidase A Expression in Highly Aggressive Prostate Cancer: Synthesis and Preclinical Evaluation of Positron Emission Tomography Tracers.ACS pharmacology & translational science · 2023Article
- Radiochemistry for positron emission tomography.Nature communications · 2023Review
- An optimized radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2023Article
- Preparation, Optimisation, and In Vitro Evaluation of [Molecules (Basel, Switzerland) · 2022Article
- Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer.Pharmaceutics · 2022Article
- The aluminium-[EJNMMI radiopharmacy and chemistry · 2021Review
- Intra-individual dynamic comparison ofScientific reports · 2020Article
- Review
- A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [Molecules (Basel, Switzerland) · 2019Review
- Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.BMC cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOverexpression of prostatic membrane antigen (PSMA) is associated with the progression and prognosis of prostate cancer. There are numerous studies using this peptide with the
resultsThe labeling up to the reactor corroborates the formation of the complex [
conclusionThe proposed method allowed the production of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.